Physician profile
Gerardo Capo
NPI 1225049505
$15,886.41
in general payments reported to CMS, 2019-2025
53 companies · $2,304 in 2025
The $2,304 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $1,014 · 2021: $348 · 2022: $4,434 · 2023: $5,019 · 2024: $1,818 · 2025: $2,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,668 · Consulting Fee: $2,456 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,667.74 |
| Consulting Fee | $2,456.00 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,788.00 | 2022-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $3,069.52 | 2020-2025 | Libtayo, Lynozyfic |
| Exelixis INC. | $1,299.01 | 2021-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $770.55 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $669.32 | 2019-2025 | Opdivo, Reblozyl |
| Genzyme Corporation | $663.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $493.63 | 2019-2025 | Lynparza, Enhertu |
| Daiichi Sankyo INC. | $470.30 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $451.73 | 2019-2025 | Keytruda, Lynparza |
| Celgene Corporation | $361.33 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $357.10 | 2019-2025 | |
| Seagen INC. | $318.24 | 2019-2023 | Tukysa |
| Janssen Biotech, INC. | $251.79 | 2019-2025 | Carvykti, Rybrevant, Darzalex |
| Genentech USA, INC. | $250.59 | 2019-2025 | Polivy, Lunsumio, Itovebi |
| Taiho Oncology, INC. | $227.79 | 2019-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $209.33 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $206.54 | 2019-2025 | |
| Eisai INC. | $185.32 | 2019-2025 | |
| Amgen INC. | $172.22 | 2019-2023 | Lumakras, Kyprolis, Vectibix |
| Incyte Corporation | $154.60 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $144.33 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Abbvie INC. | $117.25 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $116.61 | 2023-2024 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $115.70 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Array Biopharma INC | $112.02 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $108.74 | 2023-2025 | Ultomiris |
| Foundation Medicine, INC. | $70.17 | 2022-2023 | |
| Kite Pharma, INC. | $56.77 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $56.24 | 2020-2021 | |
| Emd Serono, INC. | $50.76 | 2024-2025 | |
| Astellas Pharma US INC | $45.77 | 2019-2025 | Xtandi |
| Octapharma USA, INC. | $45.26 | 2019 | |
| Stemline Therapeutics INC. | $45.24 | 2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $43.23 | 2019 | |
| Aveo Pharmaceuticals, INC. | $37.49 | 2024 | |
| Telix Pharmaceuticals | $35.29 | 2024-2025 | Illuccix |
| Geron Corporation | $35.15 | 2025 | Rytelo |
| Global Blood Therapeutics, INC. | $30.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $29.46 | 2019-2022 | |
| Macrogenics, INC. | $22.02 | 2022 | |
| Biocon Biologics INC | $20.36 | 2024 | Ogivri |
| Karyopharm Therapeutics INC. | $18.74 | 2025 | Xpovio |
| Pharmaessentia USA Corporation | $18.62 | 2025 | Besremi |
| Beone Medicines USA, INC. | $18.30 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $17.89 | 2024 | Monoferric |
| Genmab U.S., INC. | $17.44 | 2023 | Tivdak |
| Apellis Pharmaceuticals, INC. | $17.40 | 2024 | Empaveli |
| Blueprint Medicines Corporation | $16.33 | 2023 | Ayvakit |
| Epizyme, INC. | $15.00 | 2020 | |
| Legend Biotech USA INC. | $13.96 | 2024 | |
| Recordati_rare_diseases_inc. | $12.78 | 2023 | Sylvant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Capo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.